No Data
HUAKANG BIOMED: ANNUAL RESULTS ANNOUNCEMENTFOR THE YEAR ENDED 31 DECEMBER 2024
The "DeepSeek Moment" of medicine, has China’s Innovative Drugs also reached it?
Over the past four years, China's share of Global large-scale pharmaceutical Trade has surged from 5% to 30%. From research and development innovation to international mergers and acquisitions, Chinese Innovative Drugs companies are reshaping the Global pharmaceutical innovation landscape.
Express News | Huakang Biomedical - Co to Acquire 51% Equity Interest in Hunan Keyue Biotechnology
HUAKANG BIOMED (08622.HK): Xu Yongde was appointed as an independent director.
On January 22, Glonghui reported that HUAKANG BIOMED (08622.HK) announced that the Board of Directors will implement the following changes effective from January 22, 2025: (1) Zhou Jingwen has resigned as the company's independent non-executive director and will no longer serve as a member of the company's audit committee and nomination committee; and (2) Xu Yongde has been appointed as the company's independent director, as well as a member of the audit committee and nomination committee.
Express News | Huakang Biomedical - Lapse of Placing Agreement Dated 31 Dec
HUAKANG BIOMED (08622): Major shareholder Zhang Shuguang transfers 0.139 billion shares of common stock.
HUAKANG BIOMED (08622) published an announcement that the company received a notice from Zhang Shuguang, who is the company's executive director, the chairman of the Board of Directors, and...
Huakang Biomedical Holdings Vice Chairman Yim Yang Chang Sells 31% Of Holding